secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2025-05-28T23:59:59+00:00
Accession:  0000950170-25-078079
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants RMAT designation to Candel's CAN-2409 for prostate cancer; phase 3 met endpoint
--------------------------------------------------------------------------------

- RMAT designation for CAN-2409 (aglatimagene besadenovec) in newly diagnosed localized intermediate-to-high-risk prostate cancer.
- Phase 3 trial met primary endpoint: 30% risk reduction in disease-free survival (HR 0.70; p=0.0155) vs placebo.
- CAN-2409 improved prostate-specific DFS (38% risk reduction; p=0.0046) and pathological complete response (80.4% vs 63.6%; p=0.0015).
- Previously granted Fast Track; BLA submission anticipated by end of 2026 with potential rolling/priority review.
- Designation provides intensive FDA guidance to expedite development and review of the therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025078079/0000950170-25-078079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017025078079/cadl-20250528.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-078079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer